12
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Atypical antipsychotic and compliance in schizophrenia

Pages 31-39 | Published online: 12 Jul 2009
 

Abstract

Relapse of schizophrenia due to poor compliance is a major preventable source of psychiatric morbidity. One often stated reason for non-compliance is side effects from the conventional neuroleptics. Minimum effective doses are known from most drugs minimizing side-effects but low-dose maintenance regimes below these minimum doses lead to relapse. The advantages of depot medication in ensuring compliance are clearly understood, but the use of depots varies enormously in different countries. In the longer term, it is hoped that new atypical neuroleptics may have several intrinsic advantages which maximize patient compliance. Atypical neuroleptics fall roughly into five groups, the later substituted benzam-ides, mixed dopamine-serotonin receptor antagonists, specific dopamine compounds, serotonin receptor antagonists and sigma receptor antagonists. There are some early indications of improved compliance with an atypical neuroleptic, clozapine, but it is difficult to disentangle the potential massive effect of the monitoring system used in controlled studies. There is still no evidence that the new atypical neuroleptics could substantially improve the compliance in comparison with for example depot neuroleptics.

Atypical neuroleptic, Compliance, Depot neuroleptic.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.